Liquen estriado no adulto / Lichen striatus in an adult patient

O líquen estriado é uma dermatose inflamatória auto-limitada, idiopática, comum na infância e raro no adulto. Manifesta-se por pápulas violáceas, dedistribuição linear, limitadas habitualmente ao membro inferior. Apresenta-se o caso de um homem de 30 anos, caucasiano, observado por dermatose pruriginosa com 14 dias de evolução, caracterizado por erupção papulosa de distribuição linear ao longo da nádega e membro inferior direito. O exame histológico revelou líquen estriado. Fez tratamento comcorticoide tópico, tendo-se verificado resolução completa das lesõe

Lichen striatus is an uncommon inflammatory skin eruption of unknown etiology, being frequent in childhood and rare in the adult. The main manifestation are violaceous papules with linear distribution, generally limited to the lower limb. We present a case of a Caucasian male patient, aged 30, presented with a 14-days history of itching dermatosis characterized by papular eruption linearly distributed along the buttock and right lower limb. Histological examination revealed lichen striatus. He received topical steroids, with complete resolution of the lesions (AU)

High-dose cyclophosphamide followed by autologous peripheral blood progenitor cell transplantation improves the salvage treatment for persistent or sensitive relapsed malignant lymphoma

Trials have demonstrated that high-dose escalation followed by autologous transplantation can promote better long-term survival as salvage treatment in malignant lymphomas. The aim of the present nonrandomized clinical trial was to demonstrate the role of high-dose cyclophosphamide (HDCY) in reducing tumor burden and also to determine the effectiveness of HDCY followed by etoposide (VP-16) and methotrexate (MTX) in Hodgkin's disease plus high-dose therapy with peripheral blood progenitor cell (PBPC) transplantation as salvage treatment. From 1998 to 2000, 33 patients with a median age of 33 years (13-65) affected by aggressive non-Hodgkin's lymphoma (NHL) (60.6 percent) or persistent or relapsed Hodgkin's disease (39.4 percent) were enrolled and treated using high dose escalation (HDCY + HDVP-16 plus HDMTX in Hodgkin's disease) followed by autologous PBPC transplantation. On an "intention to treat" basis, 33 patients with malignant lymphomas were evaluated. The overall median follow-up was 400 days (40-1233). Thirty-one patients underwent autografting and received a median of 6.19 x 10(6)/kg (1.07-29.3) CD34+ cells. Patients who were chemosensitive to HDCY (N = 22) and patients who were chemoresistant (N = 11) presented an overall survival of 96 and 15 percent, respectively (P<0.0001). Overall survival was 92 percent for chemosensitive patients and 0 percent for patients who were still chemoresistant before transplantation (P<0.0001). Toxicity-related mortality was 12 percent (four patients), related to HDCY in two cases and to transplant in the other two. HDCY + HDVP-16 plus HDMTX in only Hodgkin's disease followed by autologous PBPC proved to be effective and safe as salvage treatment for chemosensitive patients affected by aggressive NHL and Hodgkin's disease, with acceptable mortality rates related to sequential treatment